ATE330952T1 - Tricyclische amide und harnstoff-derivate anwendbar als g-protein funktion inhibitoren und für die behandlung von proliferativen erkrankungen - Google Patents
Tricyclische amide und harnstoff-derivate anwendbar als g-protein funktion inhibitoren und für die behandlung von proliferativen erkrankungenInfo
- Publication number
- ATE330952T1 ATE330952T1 AT96909651T AT96909651T ATE330952T1 AT E330952 T1 ATE330952 T1 AT E330952T1 AT 96909651 T AT96909651 T AT 96909651T AT 96909651 T AT96909651 T AT 96909651T AT E330952 T1 ATE330952 T1 AT E330952T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- proliferative diseases
- protein function
- urea derivatives
- function inhibitors
- Prior art date
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/410,187 US5719148A (en) | 1993-10-15 | 1995-03-24 | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE330952T1 true ATE330952T1 (de) | 2006-07-15 |
Family
ID=23623621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96909651T ATE330952T1 (de) | 1995-03-24 | 1996-03-21 | Tricyclische amide und harnstoff-derivate anwendbar als g-protein funktion inhibitoren und für die behandlung von proliferativen erkrankungen |
Country Status (14)
Country | Link |
---|---|
US (4) | US5719148A (de) |
EP (1) | EP0815100B1 (de) |
JP (1) | JP3368905B2 (de) |
KR (1) | KR19980703430A (de) |
AR (1) | AR003938A1 (de) |
AT (1) | ATE330952T1 (de) |
AU (1) | AU714255B2 (de) |
CA (1) | CA2216160C (de) |
DE (1) | DE69636279T2 (de) |
ES (1) | ES2265151T3 (de) |
HU (1) | HUP9800416A2 (de) |
IL (1) | IL117604A0 (de) |
MX (1) | MX9707197A (de) |
WO (1) | WO1996030363A1 (de) |
Families Citing this family (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6316607B1 (en) * | 1986-04-30 | 2001-11-13 | Igen International, Inc. | Electrochemiluminescent assays |
US6365588B1 (en) | 1993-10-15 | 2002-04-02 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
AU769687B2 (en) * | 1995-12-22 | 2004-01-29 | Merck Sharp & Dohme Corp. | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases |
SK86198A3 (en) * | 1995-12-22 | 1999-02-11 | Schering Corp | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US5925757A (en) * | 1996-07-26 | 1999-07-20 | Schering Corporation | Method for preparing carboxamides |
US6030982A (en) * | 1996-09-13 | 2000-02-29 | Schering Corporationm | Compounds useful for inhibition of farnesyl protein transferase |
US5985879A (en) * | 1996-09-13 | 1999-11-16 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
ES2235252T3 (es) * | 1996-09-13 | 2005-07-01 | Schering Corporation | Inhibidores triciclicos de la farnesil proteina transferasa. |
ES2229340T3 (es) * | 1996-09-13 | 2005-04-16 | Schering Corporation | Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa. |
US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
US5861395A (en) * | 1996-09-13 | 1999-01-19 | Schering Corporation | Compounds useful for inhibition of farnesyl proteins transferase |
US6040305A (en) * | 1996-09-13 | 2000-03-21 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
DE69732123T2 (de) * | 1996-09-13 | 2005-12-08 | Schering Corp. | Trizyklische Verindung mit Farnesylproteintransferase inhibierender Wirkung |
KR20000068550A (ko) * | 1996-09-13 | 2000-11-25 | 쉐링 코포레이션 | 파르네실 단백질 전이효소의 억제에 유용한 화합물 |
US5994364A (en) * | 1996-09-13 | 1999-11-30 | Schering Corporation | Tricyclic antitumor farnesyl protein transferase inhibitors |
US5945429A (en) * | 1996-09-13 | 1999-08-31 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
CA2265764A1 (en) * | 1996-09-13 | 1998-03-19 | Schering Corporation | Tricyclic compounds useful as fpt inhibitors |
SK33599A3 (en) * | 1996-09-13 | 2000-03-13 | Schering Corp | Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase |
US5958890A (en) * | 1996-09-13 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6130229A (en) * | 1996-10-09 | 2000-10-10 | Schering Corporation | Tricyclic compounds having activity as RAS-FPT inhibitors |
US5972966A (en) * | 1996-12-05 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2002504151A (ja) * | 1997-06-17 | 2002-02-05 | シェーリング コーポレイション | ファルネシルタンパク質トランスフェラーゼの新規アミノオキシアミド三環式インヒビター |
US6159984A (en) | 1997-06-17 | 2000-12-12 | Schering Corporation | Farnesyl protein transferase inhibitors |
WO1998057948A1 (en) * | 1997-06-17 | 1998-12-23 | Schering Corporation | Novel n-substituted urea inhibitors of farnesyl-protein transferase |
ES2205501T3 (es) * | 1997-06-17 | 2004-05-01 | Schering Corporation | Derivados de benzo(5,6)ciclohepta(1,2b)piridina utiles para la inhibiciion de farnesil-protein-transferasa. |
US6689789B2 (en) | 1997-06-17 | 2004-02-10 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
CA2294347C (en) * | 1997-06-17 | 2008-01-29 | Schering Corporation | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase |
US5939416A (en) * | 1997-06-17 | 1999-08-17 | Schering Corporation | Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors |
US6576639B1 (en) | 1997-06-17 | 2003-06-10 | Schering Corporation | Compounds for the inhibition of farnesyl protein transferase |
US5925639A (en) * | 1997-06-17 | 1999-07-20 | Schering Corporation | Keto amide derivatives useful as farnesyl protein transferase inhibitors |
IL133392A0 (en) * | 1997-06-17 | 2001-04-30 | Schering Corp | Benzo (5, 6) cyclohepta (1, 2b) pyridine derivatives useful for inhibition of farnesyl protein transferase |
NZ501615A (en) * | 1997-06-17 | 2002-02-01 | Schering Corp | Benzo[5,6]cyclohepta[1,2-b] pyridine derivatives useful for inhibition of farnesyl protein transferase |
US6228865B1 (en) | 1997-06-17 | 2001-05-08 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
JP2002504150A (ja) * | 1997-06-17 | 2002-02-05 | シェーリング コーポレイション | ファルネシルタンパク質トランスフェラーゼの新規フェニル置換三環式インヒビター |
US6239140B1 (en) | 1997-06-17 | 2001-05-29 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6225322B1 (en) * | 1997-06-17 | 2001-05-01 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US5852034A (en) * | 1997-06-17 | 1998-12-22 | Schering Corporation | Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors |
WO1998057964A1 (en) * | 1997-06-17 | 1998-12-23 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
CN1286690A (zh) * | 1997-06-17 | 2001-03-07 | 先灵公司 | 用于抑制法尼基蛋白转移酶的化合物 |
US6218401B1 (en) | 1997-06-17 | 2001-04-17 | Schering Corporation | Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase |
US6211193B1 (en) | 1997-06-17 | 2001-04-03 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6051582A (en) * | 1997-06-17 | 2000-04-18 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US5945430A (en) * | 1997-06-17 | 1999-08-31 | Schering Corporation | Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase |
US6358968B1 (en) | 1997-06-17 | 2002-03-19 | Schering Corporation | N-substituted urea inhibitors of farnesyl-protein transferase |
JP2002510308A (ja) * | 1997-06-17 | 2002-04-02 | シェーリング コーポレイション | ファルネシルタンパク質トランスフェラーゼインヒビターとしてのベンゾ(5,6)シクロヘプタ(1,2−b)ピリジン誘導体 |
US5877177A (en) * | 1997-06-17 | 1999-03-02 | Schering Corporation | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
WO1998057961A1 (en) * | 1997-06-17 | 1998-12-23 | Schering Corporation | Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase |
US5958940A (en) * | 1997-09-11 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful as inhibitors of farnesyl-protein transferase |
US6632455B2 (en) | 1997-12-22 | 2003-10-14 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
US6096757A (en) | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
EP1090011A4 (de) | 1998-07-02 | 2005-04-06 | Merck & Co Inc | Inhibitoren von prenyl-protein-transferase |
AU760027B2 (en) | 1998-07-02 | 2003-05-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6307048B1 (en) | 1998-11-20 | 2001-10-23 | Schering Corporation | Enantioselective alkylation of tricyclic compounds |
US6800636B2 (en) * | 1998-12-18 | 2004-10-05 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6372747B1 (en) * | 1998-12-18 | 2002-04-16 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6362188B1 (en) * | 1998-12-18 | 2002-03-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6271378B1 (en) | 1998-12-18 | 2001-08-07 | Schering Corporation | Process for preparing tricyclic compounds having antihistaminic activity |
US6432959B1 (en) | 1998-12-23 | 2002-08-13 | Schering Corporation | Inhibitors of farnesyl-protein transferase |
PE20001566A1 (es) | 1999-03-26 | 2001-02-05 | Ucb Sa | Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas |
US6686502B1 (en) | 1999-03-26 | 2004-02-03 | Ucb S.A. | Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
AU2001227757A1 (en) | 2000-01-12 | 2001-07-24 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
AU2001229320A1 (en) | 2000-01-12 | 2001-07-24 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
US6566385B2 (en) | 2000-01-12 | 2003-05-20 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6610722B2 (en) | 2000-04-10 | 2003-08-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US7342016B2 (en) * | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
AR033680A1 (es) * | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
CA2429720C (en) * | 2000-11-29 | 2009-12-29 | Schering Corporation | Tricyclic compounds useful for the inhibition of farnesyl protein transferase |
US6703400B2 (en) | 2001-02-23 | 2004-03-09 | Schering Corporation | Methods for treating multidrug resistance |
US20030059857A1 (en) * | 2001-09-17 | 2003-03-27 | Schering Corporation | G-protein coupled receptor and methods |
US7217796B2 (en) * | 2002-05-24 | 2007-05-15 | Schering Corporation | Neutralizing human anti-IGFR antibody |
ES2340806T3 (es) | 2002-10-03 | 2010-06-09 | Schering Corporation | Alquilacion enantioselectiva de compuestos triciclicos. |
US7417026B2 (en) | 2003-08-13 | 2008-08-26 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
PE20050928A1 (es) * | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
EP1744751A4 (de) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | Verfahren zur behandlung von synucleinopathien |
WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
CN101222926B (zh) * | 2005-04-15 | 2013-07-17 | 默沙东公司 | 用于治疗或预防癌症的方法和组合物 |
EP1888050B1 (de) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs |
AU2006259536A1 (en) | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
WO2007080140A1 (en) * | 2006-01-13 | 2007-07-19 | F. Hoffmann-La Roche Ag | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
MX2009007200A (es) | 2007-01-10 | 2009-07-15 | Angeletti P Ist Richerche Bio | Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp). |
EP2132177B1 (de) | 2007-03-01 | 2013-07-17 | Novartis AG | Pim-kinase-hemmer und verfahren zu ihrer verwendung |
EP2152700B1 (de) | 2007-05-21 | 2013-12-11 | Novartis AG | Csf-1r-hemmer, zusammensetzungen und anwendungsverfahren |
AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
BRPI0920927A2 (pt) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JP6073677B2 (ja) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 縮合複素環式化合物およびそれらの使用 |
EA023838B1 (ru) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
CA2791613A1 (en) | 2010-03-16 | 2011-09-22 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
EP2608669B1 (de) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
KR20130121891A (ko) * | 2010-12-01 | 2013-11-06 | 얀센 파마슈티카 엔.브이. | Ccr2의 4-치환된-사이클로헥실아미노-4-피페리디닐-아세트아미드길항제 |
EP2654748B1 (de) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
EP3453762B1 (de) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
JP6280554B2 (ja) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Erk阻害剤である新規化合物 |
WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
ME02925B (de) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Zusammensetzungen und verfahren zur behandlung von krebs |
TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲hdm2抑制劑之經取代咪唑吡啶 |
CN103044395B (zh) * | 2012-12-31 | 2015-03-11 | 天津药物研究院 | 含有地氯雷他定结构的氨基酸类衍生物、其制备方法和用途 |
EP2951180B1 (de) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8-substituierte purine als hdm2-inhibitoren |
PT3466930T (pt) | 2013-02-08 | 2022-08-19 | Gen Mills Inc | Produto alimentar com baixo teor de sódio |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の多環阻害剤 |
ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
EP3236959A4 (de) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Hemmer der cyclinabhängigen kinase 7 (cdk7) |
CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
EP3609922A2 (de) | 2017-04-13 | 2020-02-19 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp-alpha-antikörper |
CN107501323B (zh) * | 2017-08-28 | 2019-05-14 | 四川大学 | 一种三环膦酸酯类化合物的制备方法 |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
IL292616A (en) * | 2019-10-31 | 2022-07-01 | Jd Bioscience Inc | Tricyclic compounds, preparations containing them and their uses |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4355036A (en) * | 1980-06-19 | 1982-10-19 | Schering Corporation | Tricyclic-substituted piperidine antihistamines |
US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
US4826853A (en) * | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
US5104876A (en) * | 1988-04-28 | 1992-04-14 | Schering Corporation | Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use |
CA1341370C (en) * | 1988-04-28 | 2002-06-18 | John J. Powinski | Fused polycyclic compounds, methods of manufacture, and their use as paf antagonists, antihistamines and/or antiinflammatory agents |
US5393890A (en) * | 1988-06-02 | 1995-02-28 | Ajinomoto Co., Inc. | Piperidine derivatives and hypotensives containing the same |
US4863931A (en) * | 1988-09-15 | 1989-09-05 | Schering Corporation | Antihistaminic fluoro substituted benzocycloheptapyridines |
US6083917A (en) * | 1990-04-18 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods and compositions for the identification, characterization and inhibition of farnesyltransferase |
US5141851A (en) * | 1990-04-18 | 1992-08-25 | Board Of Regents, The University Of Texas System | Isolated farnesyl protein transferase enzyme |
IL98572A (en) * | 1990-06-22 | 1995-07-31 | Schering Corp | Bite-benzo or benzopyrido compounds Cyclohepta piperidine, piperidylidene and piperazine, preparations and methods of use. |
CA2098198A1 (en) * | 1990-12-18 | 1992-06-18 | Ann Christie King | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
JPH0676403B2 (ja) * | 1991-01-18 | 1994-09-28 | エスエス製薬株式会社 | 新規なベンゾ[5,6 シクロヘプタ[1,2−b ピリジン誘導体及びこれを含有する抗アレルギー剤 |
US5340828A (en) * | 1991-09-30 | 1994-08-23 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
US5643909A (en) * | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
-
1995
- 1995-03-24 US US08/410,187 patent/US5719148A/en not_active Expired - Lifetime
- 1995-05-25 US US08/450,433 patent/US5807853A/en not_active Expired - Lifetime
- 1995-05-25 US US08/450,064 patent/US5714609A/en not_active Expired - Lifetime
- 1995-05-25 US US08/450,288 patent/US5696121A/en not_active Expired - Lifetime
-
1996
- 1996-03-21 CA CA002216160A patent/CA2216160C/en not_active Expired - Fee Related
- 1996-03-21 WO PCT/US1996/003314 patent/WO1996030363A1/en active IP Right Grant
- 1996-03-21 AT AT96909651T patent/ATE330952T1/de not_active IP Right Cessation
- 1996-03-21 ES ES96909651T patent/ES2265151T3/es not_active Expired - Lifetime
- 1996-03-21 DE DE69636279T patent/DE69636279T2/de not_active Expired - Lifetime
- 1996-03-21 HU HU9800416A patent/HUP9800416A2/hu unknown
- 1996-03-21 MX MX9707197A patent/MX9707197A/es not_active IP Right Cessation
- 1996-03-21 AU AU53077/96A patent/AU714255B2/en not_active Ceased
- 1996-03-21 IL IL11760496A patent/IL117604A0/xx unknown
- 1996-03-21 EP EP96909651A patent/EP0815100B1/de not_active Expired - Lifetime
- 1996-03-21 JP JP52943496A patent/JP3368905B2/ja not_active Expired - Fee Related
- 1996-03-21 KR KR1019970706834A patent/KR19980703430A/ko not_active Application Discontinuation
- 1996-03-22 AR ARP960101891A patent/AR003938A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US5696121A (en) | 1997-12-09 |
JPH10505105A (ja) | 1998-05-19 |
JP3368905B2 (ja) | 2003-01-20 |
EP0815100B1 (de) | 2006-06-21 |
AU5307796A (en) | 1996-10-16 |
CA2216160C (en) | 2001-10-30 |
EP0815100A1 (de) | 1998-01-07 |
AR003938A1 (es) | 1998-09-30 |
US5714609A (en) | 1998-02-03 |
US5719148A (en) | 1998-02-17 |
DE69636279D1 (de) | 2006-08-03 |
US5807853A (en) | 1998-09-15 |
DE69636279T2 (de) | 2007-06-21 |
KR19980703430A (ko) | 1998-11-05 |
WO1996030363A1 (en) | 1996-10-03 |
AU714255B2 (en) | 1999-12-23 |
MX9707197A (es) | 1997-11-29 |
CA2216160A1 (en) | 1996-10-03 |
HUP9800416A2 (hu) | 1999-06-28 |
ES2265151T3 (es) | 2007-02-01 |
IL117604A0 (en) | 1996-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE330952T1 (de) | Tricyclische amide und harnstoff-derivate anwendbar als g-protein funktion inhibitoren und für die behandlung von proliferativen erkrankungen | |
ATE294791T1 (de) | Tricyclische amid-derivate verwendbar als g- protein funktion inhibitoren und für die behandlung von proliferativen erkrankungen | |
DE69637105D1 (de) | Tricyclische derivate anwendbar als g-protein inhibitoren und für die behandlung von proliferative erkrankungen | |
ATE309238T1 (de) | Zur hemming der g-protein-funktion und zur behandlung proliferativer krankheiten geeignete tricyclische amide | |
ATE239472T1 (de) | Trycyclische derivate zur inhibierung der g- protein funktion und für die behandlung von proliferativen erkrankungen | |
DE69626104T2 (de) | Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und zur behandlung von proliferativen erkrankungen | |
DE69630324D1 (de) | Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen | |
DE69604700T2 (de) | Verfahren und vorrichtung zum erleichtern der anpassung von sensoren an pulsoximetern | |
DE69611927T2 (de) | Vorrichtung und verfahren zum bestimmen des standorts von objekten | |
DE69424917T2 (de) | Verfahren und Vorrichtung zur ablativen Behandlung von elastomerischen Produkten | |
ATE236529T1 (de) | Antiparasitäre zusammensetzung zur behandlung und zum schutz von haustieren | |
DE69434397D1 (de) | Tricyclische Amide und Harnstoffderivate zur Inhibierung der G-Protein Funktion und für die Behandlung von proliferativen Behandlungen | |
DE69625872T2 (de) | Vorrichtung und Verfahren zum Verhindern der Ausbreitung von Mikroben | |
DE59602767D1 (de) | Vorrichtung zum umfänglichen und seitlichen Verstellen des Plattenzylinders | |
DE69609199D1 (de) | Lacton derivate von 17.beta.-carboxy, carbothio und amide androstanverbindungen | |
DE69433201D1 (de) | Oligonukleotide und Verfahren zum Nachweis von Bakterien | |
DE59508433D1 (de) | Verfahren zum Entgräten von Fischen und Einrichtung zum Durchführen des Verfahrens | |
DE69520268T2 (de) | Behandlung von Legierungen und danach hergestellte Gegenstände | |
DE59702626D1 (de) | Verfahren und Vorrichtung zum Messem des Durchmessers exzentrisch umlaufender Werkstücke | |
DE69720731D1 (de) | Verfahren und zusammensetzung für die antiparasitäre behandlung der umgebung vontieren | |
ATA169298A (de) | Verfahren und anlage zum kontinuierlichen herstellen von bauelementen | |
ATA93695A (de) | Mittel zur behandlung von strahlenschäden | |
DE69614286T2 (de) | Verfahren und Anlage zur Behandlung von fettigen Abfällen | |
ZA9610735B (en) | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases | |
DE19880496D2 (de) | Vorrichtung zum hygienischen Duschen oder Applizieren eines Klistiers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |